NASDAQ:TCDA - Tricida Stock Price, Forecast & News

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) announced its earnings results on Thursday, November, 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

3 brokerages have issued 12-month price targets for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they anticipate Tricida's share price to reach $51.50 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

News stories about TCDA stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Tricida.

Tricida saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 4,340,000 shares, an increase of 8.0% from the November 28th total of 4,020,000 shares. Based on an average daily trading volume, of 303,500 shares, the short-interest ratio is currently 14.3 days. Currently, 12.2% of the company's shares are sold short. View Tricida's Current Options Chain.

Some companies that are related to Tricida include The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), GW Pharmaceuticals PLC- (GWPH), Ocular Therapeutix (OCUL), AT&T (T), Affimed (AFMD) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $34.04.

Tricida has a market capitalization of $1.69 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]